United States - English - NLM (National Library of Medicine)

aspen veterinary resources ltd. - ceftiofur sodium (unii: nhi34is56e) (ceftiofur - unii:83jl932i1c) - cattle ceftiofur sodium sterile powder is indicated for treatment of bovine respiratory disease (shipping fever, pneumonia) associated with mannheimia haemolytica , pasteurella multocida and histophilus somni . ceftiofur sodium sterile powder is also indicated for treatment of acute bovine interdigital necrobacillosis (foot rot, pododermatitis) associated with fusobacterium necrophorum and bacteroides melaninogenicus . swine ceftiofur sodium sterile powder is indicated for treatment/control of swine bacterial respiratory disease (swine bacterial pneumonia) associated with actinobacillus (haemophilus) pleuropneumoniae , pasteurella multocida , salmonella choleraesuis and streptococcus suis . sheep ceftiofur sodium sterile powder is indicated for treatment of sheep respiratory disease (sheep pneumonia) associated with mannheimia haemolytica and pasteurella multocida . goat ceftiofur sodium sterile powder is indicated for treatment of caprine respiratory disease (goat pneumonia) associated with mannheimia ha

United States - English - NLM (National Library of Medicine)

aspen veterinary resources ltd - amoxicillin anhydrous (unii: 9em05410q9) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - umbrellin™ drops are indicated in the treatment of: dogs: skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of the following organisms: β-lactamase-producing staphylococcus aureus , non-β-lactamase-producing staphylococcus aureus, staphylococcus spp., streptococcus spp., and e. coli . periodontal infections due to susceptible strains of both aerobic and anaerobic bacteria. umbrellin™ drops has been shown to be clinically effective for treating cases of canine periodontal disease. cats: skin and soft tissue infections such as wounds, abscesses, and cellulitis/dermatitis due to susceptible strains of the following organisms: β-lactamase-producing staphylococcus aureus, non-β-lactamase-producing staphylococcus aureus, staphylococcus spp., streptococcus spp., e. coli, pasteurella multocida, and pasteurella spp. urinary tract infections (cystitis) due to susceptible strains of e. coli . therapy may be initiated with umbre

United States - English - NLM (National Library of Medicine)

aspen veterinary resources®, ltd. - maropitant citrate (unii: lxn6s3999x) (maropitant - unii:4xe2t9h4dh) - ceritant (maropitant citrate) tablets are indicated for the prevention of acute vomiting and the prevention of vomiting due to motion sickness in dogs.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ciprofloxacin, quantity: 2 mg/ml - injection, intravenous infusion - excipient ingredients: lactic acid; glucose monohydrate; water for injections - aspen ciprofloxacin injection for intravenous infusion is indicated for use in the following. hospitalised adult patients in whom oral ciprofloxacin is indicated but cannot be administered or where the oral form is inappropriate. for the treatment of serious or life-threatening infections due to sensitive organisms involving the following organ systems. lower respiratory tract infections (gram-negative organisms), skin and skin structure, septicaemia, bone and joint, urinary tract. inhalational anthrax (post exposure): to reduce the incidence or progression of disease following exposure to aerosolized bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. if anaerobic organisms are suspected of contributing to the infection, use of other suitable drugs should be considered. strains neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiological agents, additional therapy should be considered.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ciprofloxacin, quantity: 2 mg/ml - injection, intravenous infusion - excipient ingredients: lactic acid; glucose monohydrate; water for injections - aspen ciprofloxacin injection for intravenous infusion is indicated for use in the following. hospitalised adult patients in whom oral ciprofloxacin is indicated but cannot be administered or where the oral form is inappropriate. for the treatment of serious or life-threatening infections due to sensitive organisms involving the following organ systems. lower respiratory tract infections (gram-negative organisms), skin and skin structure, septicaemia, bone and joint, urinary tract. inhalational anthrax (post exposure): to reduce the incidence or progression of disease following exposure to aerosolized bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. if anaerobic organisms are suspected of contributing to the infection, use of other suitable drugs should be considered. strains neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiological agents, additional therapy should be considered.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - codeine phosphate hemihydrate, quantity: 30 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; magnesium stearate - aspen codeine tablets are indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - fluconazole, quantity: 200 mg - injection, solution - excipient ingredients: sodium chloride; water for injections - fluconazole injection is indicated for the following conditions but should be used only when fluconazole cannot be administered orally: 1. treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note: data suggest that the clinical efficacy of fluconazole is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. 2. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with acquired immune deficiency syndrome (aids). 3. treatment of oropharyngeal and oesophageal candidiasis in patients with aids and other immunosuppressed patients. 4. secondary prophylaxis of oropharyngeal candidiasis in patients with human immunodeficiency virus (hiv) infection. 5. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note: it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life-threatening candida infections. until such data are available, amphotericin b remains the drug of choice.

United States - English - NLM (National Library of Medicine)

aspen veterinary resources - iodine (unii: 9679tc07x4) (iodine - unii:9679tc07x4) - directions: iodine concentrate must be diluted before use do not mix with anything but cool, potable water for use only in a dispensing system recommended by ecolab dilution parameter: a dilute solution of a 0.5% iodine teat dip will consist of 87.5% potable water and 12.5% iodine concentrate by volume. a dilute solution of a 1% iodine teat dip will consist of 75% potable water and 25% iodine concentrates by volume. important: do not mix iodine concentrate or diluted iodine concentrate with any other products unless specified in the product use instructions. if transferred from this container to any other, make sure that the other container is thoroughly pre-cleaned and bears the proper container labeling for iodine concentrate. if product in dip cup becomes visibly dirty, discard contents and replenish with diluted, ready-to-use product. do not reuse or return any unused product to the original container. before milking: wash teats thoroughly just prior to next milking with appropriate udder wash solution

United States - English - NLM (National Library of Medicine)

aspen veterinary resources - flunixin meglumine (unii: 8y3jk0jw3u) (flunixin - unii:356ib1o400) - there are no known contraindications to this drug in swine when used as directed. do not use in animals showing hypersensitivity to flunixin meglumine. use judiciously when renal impairment or gastric ulceration is suspected.

United States - English - NLM (National Library of Medicine)

aspen veterinary resources - ceftiofur hydrochloride (unii: 6822a07436) (ceftiofur - unii:83jl932i1c) - swine: cefenil rtu is indicated for treatment/control of swine bacterial respiratory disease (swine bacterial pneumonia) associated with actinobacillus (haemophilus) pleuropneumoniae, pasteurella multocida, salmonella choleraesuis and streptococcus suis. cattle: cefenil rtu is indicated for treatment of the following bacterial diseases: shake for 90 seconds to ensure complete resuspension before using. swine: administer intramuscularly at a dosage of 1.36 to 2.27 mg ceftiofur equivalents/lb (3.0 to 5.0 mg/kg) bw (1 ml of sterile suspension per 22 to 37 lb bw). treatment should be repeated at 24 h intervals for a total of three consecutive days. cattle: - for bovine respiratory disease and acute bovine interdigitai necrobaciilosis: administer by intramuscular or subcutaneous administration at the dosage of 0.5 to 1.0 mg ceftiofur equivalents/lb (1.1 to 2.2 mg/kg) bw (1 to 2 ml sterile suspension per 100 lb bw). administer daily at 24 h intervals for a total of three consecutive days. additional treatments